HeartBeam’s synthesised 12-lead electrocardiogram (ECG) has met the clinical endpoints in the VALID-ECG pivotal study, assessing non-life-threatening arrhythmias. In the study, the mean difference in ...
(RTTNews) - HeartBeam, Inc., (BEAT), a medical technology company, Tuesday said its synthesized 12-lead electrocardiogram (ECG) met the clinical endpoints in the VALID-ECG pivotal study. The study ...
HeartBeam, Inc. (BEAT), (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that its groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback